Effects of sildenafil citrate (Viagra) on choroidal congestion

Ophthalmologica

Volumn 216, Issue 6, 2002, Pages 455-458

  McCulley, Timothy J ^a   Luu, James K ^b   Marmor, Michael F ^b   Feuer, William J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Blood flow; Choroid; Choroidal congestion; Color vision; Contrast sensitivity; Ocular; Ophthalmology; Side effects; Sildenafil; Viagra

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CHOROID; COLOR DISCRIMINATION; COLOR VISION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; THICKNESS;

ADULT; CHOROID; CHOROID HEMORRHAGE; COLOR PERCEPTION; CONTRAST SENSITIVITY; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; ULTRASONOGRAPHY;

EID: 0036960524     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067549     Document Type: Article

References (16)

1. Food and Drug Administration (FDA a) Joint Clinical Review. Study 101/101B: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter, long-term dose-response study to assess the efficacy and safety of sildenafil (UK-92, 480) administered prior to sexual activity to male patients with erectile dysfunction, pp 99-102.
2. Food and Drug Administration (FDA b) Joint Clinical Review. Study 148-102: A double-blind, randomized, placebo controlled, parallel-group, fixed-dose, multicenter, study to assess the efficacy and safety of UK-92, 480 administered over six months to male patients with erectile dysfunction, pp 104-110.
3. Food and Drug Administration (FDA c) Joint Clinical Review. Study 148-103: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible dose escalation study to assess the efficacy and safety of sildenafil administered as required to male patients with erectile dysfunction, pp 111-117.
4. Utinger RD: A pill for impotence: N Engl J Med 1998;338:148-149.
5. Wallis RM, Corbin JD, Francis SH, Ellis P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
6. Food and Drug Administration (FDA d) Joint Clinical Review. Study 148-004: Phase 1 investigator-blind, placebo-controlled evaluation of safety, toleration, and pharmacokinetics of sildenafil following escalating single oral doses in healthy male volunteers, pp 96-98.
7. Food and Drug Administration (FDA e) Joint Clinical Review. Study 148-228: An open, randomized, single oral dose, four way crossover study to determine the dose proportionality of the pharmacokinetics of sildenafil in healthy male volunteers over the dose range 15 mg to 200 mg, pp 167-169.
8. Zusman RM, Morales A, Glasser DB, Osteroh IH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
9. Food and Drug Administration (FDA f) Joint Clinical Review. Study 148-223: An open, randomized, placebo-controlled, four period crossover study to assess the effect of orally administered sildenafil (50, 100 and 200 mg) on visual function in healthy male volunteers, pp 160-161.
10. Food and Drug Administration (FDA g) Review and Evaluation of Pharmacology and Toxicology Data. Section 1.2.3.6 Pharmacology: Activities related to mechanism of action: Functional effects on other tissues expressing PDE5 enzyme: Retinal effects, 1998, pp 19-21.
11. Marmor MF, Kessler R: Sildenafil (Viagra) and ophthalmology. Sur Ophthalmol 1999;44(2):153-162.
12. Siu K, Grunwald JE, Jacob SS, Dupont J: Effect of Viagra on ocular circulation. Invest Ophthalmol Vis Sci 2000;41(suppl):S98.
13. Food and Drug Administration (FDA h) Joint Clinical Review. Animal pharmacology: Mechanism of action, p 4.
14. Sponsel WE, Sandoval S, Chen N, DuPont J: Effects of sildenafil (Viagra) on ocular blood perfusion and contrast sensitivity. Invest Ophthalmol Vis Sci 2000;41(suppl):S98.
15. Food and Drug Administration (FDA i) Joint Clinical Review. Study 148-232: A randomized, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral table dose of sildenafil (200 mg) on visual function (electroretinogram) in healthy male volunteers and patients with diabetic retinopathy.
16. Grunwald JE, Koppiker NP, Hodges M: Visual adverse events in patients with eye disorders who received sildenafil for the treatment of erectile dysfunction. Invest Ophthalmol Vis Sci 1999;40(suppl):S767.